Vital Factors & Major Industry Leaders Boosting the Global Industry Growth for Brain Monitoring Market

The increasing incidence of neurological disorders, rising awareness about neurodegenerative diseases, growth in the number of traumatic brain injuries, and technological advancements are major factors driving the demand for brain monitoring devices. On the other hand, the shortage of trained professionals to effectively operate brain monitoring devices and unfavorable reimbursement policies are restraining the growth of Brain Monitoring Market.

Based on end user, the brain monitoring market is segmented into hospitals, neurology centers, clinics and ambulatory surgical centers (ASCs), ambulances, and other end users. In 2016, the hospitals segment is expected to dominate the global brain monitoring market. Hospitals have access to all kinds of equipment for proper diagnosis and also the inflow of patients is considerably higher in hospitals as compared to other healthcare settings. Moreover, hospitals have a better capacity to afford the high installation and maintenance costs of these complex devices. As a result, the adoption of brain monitoring devices is higher in hospitals as compared to other healthcare settings.

Based on region, the global brain monitoring market is segmented into North America, Europe, Asia, and the Rest of the World (RoW). North America is expected to account for the largest share of the market by the end of 2016. This large share can be attributed to the increase in the geriatric population, growing incidence of various neurodegenerative and sleep disorders, availability of insurance coverage for brain monitoring techniques, government initiatives to support technological advancement in the field of neurosciences, and increasing awareness about the benefits of early diagnosis of diseases.

The key growth strategies adopted by the top players profiled in the report include partnerships, collaborations, contracts, and agreements; approvals, clearances and product/technology launches and upgrades; expansions; acquisitions; and other strategies (include investments, grants, and funding).

Read More Detailed Information | Download the PDF Brochure@ http://bit.ly/2MFXgpr

Prominent players in the brain monitoring market include Natus Medical Inc. (U.S.), Nihon Kohden Corporation (Japan), Philips Healthcare (Netherlands), GE Healthcare (U.K.), Siemens Healthineers (Germany), Compumedics Ltd. (Australia), Electrical Geodesics Incorporated (U.S.), Medtronic plc (Ireland), CAS Medical Systems, Inc. (U.S.), and Advanced Brain Monitoring (U.S.).

The brain monitoring is a highly fragmented market with several big as well as emerging players fighting to secure a larger market share. The majority of the companies in the brain monitoring market are based in the U.S.

Partnerships, agreements, contracts, and collaborations accounted for the largest share of the total growth strategies adopted by key players in the brain monitoring market. Companies adopted this strategy to develop advanced products in the market, strengthen their market shares, expand their customer base, and cater to the unmet needs of their customers. Philips Healthcare (Netherlands), GE Healthcare (U.K.), Compumedics Limited (Australia), Electrical Geodesics, Inc. (U.S.), CAS Medical Systems, Inc. (U.S.), and Advanced Brain Monitoring (U.S.) are some of the leading companies that adopted this strategy.

Read More@ 

https://www.marketsandmarkets.com/Market-Reports/brain-monitoring-devices-market-909.html

Air Quality Monitoring System Market is Projected to Generate the Revenue Worth 4.90 Billion USD by 2022

The major factors driving the growth of the Air Quality Monitoring System Market include the supportive government regulations for effective air pollution monitoring and control, ongoing initiatives towards the development of environment-friendly industries, increasing public-private funding for effective air pollution monitoring, rising levels of air pollution, and increasing public awareness related to the environmental and healthcare implications of air pollution.

By product, the indoor monitors segment accounted for the largest share of the market in 2017

Based on product, the air quality monitoring system market is segmented into indoor monitors (comprising fixed and portable monitors), outdoor monitors (comprising fixed, portable, dust, and particulate monitors as well as AQM stations), and wearable monitors. The indoor monitors segment dominated the AQMS market in 2017. The large share of this segment is attributed to the increasing adoption of smart home and green-building technologies and growing consumer preference for pollution-free indoor environments.

Government agencies and academic institutes held the largest share of the AQMS market in 2017

On the basis of end user, the air quality monitoring system market is segmented into government agencies and academic institutes, commercial and residential users, petrochemical industry, power generation plants, pharmaceutical industry, smart city authority, and other end users. The government agencies and academic institutes segment accounted for the largest share in 2017. The large share of this segment can be attributed to the presence of stringent environmental regulations, rising government investments for effective AQM, and increased installation of AQM stations worldwide.

Get 10% Free Customization on This Report@ 

https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=183784537

In 2017, North America dominated the AQMS market

Geographically, the AQMS market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. North America held the largest share of the market in 2017. Factors such as easy accessibility and fast adoption of advanced technologies among key stakeholders and the presence of stringent government regulations for effective pollution monitoring and control are contributing to the large share of the North American region.

The major players operating in the AQMS market include Thermo Fisher Scientific (US), Teledyne Technologies, Inc. (US), Siemens Ltd. (Germany), Emerson Electric Co. (US), and General Electric (US).

Target Audience:

• Manufacturers and distributors of AQM products
• AQM software developers
• Research laboratories and academic institutes
• Air pollution monitoring committees
• Pharmaceutical and biotechnology companies
• Government and non-government agencies
• National and regional air pollution control boards and organizations
• Petrochemical and biofuel product manufacturing companies
• Metals and mining companies
• Oil and gas production and distribution companies
• Gas operators, distributors, and regulators
• Power generation and power distribution units
• Municipalities and municipal corporations
• Sewage and wastewater treatment plants
• Food and beverages manufacturing companies
• Market research and consulting firms

Read More@ 
https://www.marketsandmarkets.com/Market-Reports/air-quality-monitoring-equipment-market-183784537.html

Neuromonitoring Market is Expected to Generate the Revenue at a CAGR of 6.8% in the Near Future

The increasing incidence of neurological disorders, rising awareness about neurodegenerative diseases, growth in the number of traumatic brain injuries, and technological advancements are major factors driving the demand for brain monitoring devices. On the other hand, the shortage of trained professionals to effectively operate brain monitoring devices and unfavorable reimbursement policies are restraining the growth of Neuromonitoring Market.

The global Neuromonitoring Market is expected to reach USD 12.22 Billion by 2021 from USD 8.80 Billion in 2016, growing at a CAGR of 6.8% from 2016 to 2021.

                                             --> Global Industry Segmentation <--

On the basis of type, the brain monitoring devices market is categorized into MRI scanners, CT scanners, PET scanners, electroencephalography devices, cerebral oximeters, intracranial pressure monitors, sleep monitoring devices, electromyography devices, TCD devices, and magnetoencephalography devices. The MRI scanners segment is expected to account for the largest share of the global Neuromonitoring Market in 2016. 

MRI is a premium and sensitive imaging test for brain imaging in routine clinical practice. It provides superior images with contrast among different types of normal body tissues and between pathologic and normal tissues, thus allowing to investigate the anatomy and function of the human brain in terms of both health and disease. MRI is also a widely used technique for medical diagnosis and staging of diseases like cancer.

Based on disease type, the Neuromonitoring Market is categorized into epilepsy, dementia, Parkinson’s disease, Huntington’s disease, headache disorders, strokes, traumatic brain injuries, sleep disorders, and other diseases. The traumatic brain injuries segment is expected to account for the largest share of the global market in 2016. The increasing occurrence of falls, blunt trauma, and motor vehicle crashes (among other causes of traumatic brain injuries), alongside the growing aging population (who are more susceptible to such injuries), is contributing to the growth of this market segment.

Feel Free to Connect With Our Research Experts for More Detailed Information 

Based on end user, the Neuromonitoring Market is segmented into hospitals, neurology centers, clinics and ambulatory surgical centers (ASCs), ambulances, and other end users. In 2016, the hospitals segment is expected to dominate the global Neuromonitoring Market. Hospitals have access to all kinds of equipment for proper diagnosis and also the inflow of patients is considerably higher in hospitals as compared to other healthcare settings. Moreover, hospitals have a better capacity to afford the high installation and maintenance costs of these complex devices. As a result, the adoption of brain monitoring devices is higher in hospitals as compared to other healthcare settings.

                                                   --> Geographical Analysis <--

North America, comprising the U.S. and Canada, is expected to account for the largest share of the global market in 2016. The overall growth of the market in North America is primarily driven by the growing incidence of various neurodegenerative and sleep disorders, availability of insurance coverage for brain monitoring techniques, and government initiatives to support technological advancement in the field of neurosciences.

The prominent players in the Neuromonitoring Market are Natus Medical Inc. (U.S.), Nihon Kohden Corporation (Japan), Philips Healthcare (Netherlands), GE Healthcare (U.K.), Siemens Healthineers (Germany), Compumedics Ltd. (Australia), Electrical Geodesics Incorporated (U.S.), Medtronic plc (Ireland), CAS Medical Systems, Inc. (U.S.), and Advanced Brain Monitoring (U.S.).

Read More@ 

https://www.marketsandmarkets.com/Market-Reports/brain-monitoring-devices-market-909.html

Clinical Trial Management System Market worth 1,065.6 Million USD by 2022

The major factors driving the growth of the Clinical Trial Management System Market include the significant partnerships between Asian CROs and pharma companies, rising number of clinical trials in both developing and developed nations, availability of advanced and upgraded CTMS solutions, and rising government support for clinical trials in Asian countries.

The global Clinical Trial Management System Market is expected to reach 1,065.6 million by 2022 from USD 590.0 million in 2017, at a CAGR of 12.6%. 

The pharmaceutical and biopharmaceutical companies segment is expected to hold the largest share of the market in 2017

By end user, the CTMS market is segmented into pharmaceutical and biopharmaceutical companies, contract research organizations, medical device companies, and others. The pharmaceutical and biopharmaceutical companies segment is further subsegmented into large pharmaceutical companies and mid-small pharmaceutical companies. The pharmaceutical and biopharmaceutical companies segment is expected to account for the largest share of the Clinical Trial Management System Market in 2017. The largest share is attributed to the increasing adoption of CTMS software during drug clinical trials by pharmaceutical and biopharmaceutical companies.

The enterprise CTMS segment is estimated to account for the largest share of the CTMS market by type in 2017

The CTMS market is segmented into enterprise CTMS and site CTMS on the basis of type. The enterprise CTMS segment is expected to command the largest share of the global CTMS market in 2017, and is expected to grow at the highest CAGR in the forecast period. This is attributed to the widespread adoption of enterprise CTMS by majority of the end users.

Feel Free to Connect With Our Research Experts for More Detailed Information on This Study

North America is expected to dominate the Clinical Trial Management System Market during the forecast period

Geographically, the CTMS market is segmented into North America, Europe, Asia Pacific, and the rest of the world. North America is expected to account for the largest share of the global Clinical Trial Management System Market during the forecast period (2017-2022). Factors such as rising number of on-going clinical trials (especially in the US), presence of leading players from both demand and supply sides, and government funding for clinical research are contributing to the large share of the North American region.

Major players in Clinical Trial Management System Market include Oracle Corporation (US), Medidata Solutions, Inc. (US), PAREXEL International Corporation. (US), Bioclinica. (US), Bio-Optronics, Inc. (US), and IBM (US). Product launches, partnerships, collaborations, agreements, and market expansions were the key strategies adopted by players to grow and expand their presence in the clinical trial management system market.

Read More@ 
https://www.marketsandmarkets.com/Market-Reports/clinical-trial-management-systems-market-470.html

Bioelectric Medicine Market is Set to Generate the Revenue at a CAGR of 7.9%

A number of factors such as rising geriatric population, regulatory approval for new and advanced electroceuticals, growing investments and funds for the development of novel therapies and electroceuticals, rising prevalence of neurological disorders, and growing prevalence of hearing loss are expected to drive the growth of the Bioelectric Medicine Market during the forecast period.

The implantable cardioverter defibrillators segment is expected to account for the largest share of the bioelectric medicine market in 2016. However, the retinal implants segment is projected to grow at the highest CAGR during the forecast period.

Based on type of device, the bioelectric medicine market is segmented into implantable electroceutical devices, and non-invasive electroceutical devices. The implantable electroceutical devices segment is expected to account for the largest share of the market in 2016; while, the non-invasive electroceutical devices segment is projected to grow at the highest CAGR in the forecast period.

In this report, the global bioelectric medicine market is segmented on the basis of product, type of device, application, end user, and region. Based on product, the market is categorized into implantable cardioverter defibrillators, cardiac pacemakers, spinal cord stimulators, cochlear implants, deep brain stimulators, transcutaneous electrical nerve stimulators, vagus nerve stimulators, sacral nerve stimulators, retinal implants, and other electrical stimulators (gastric electrical stimulators, transcranial magnetic stimulators, and respiratory electrical stimulators). 

Based on application, the bioelectric medicine market is segmented into product wise such as cardiac pacemakers and implantable cardioverter defibrillators (used for arrhythmia), cochlear implants (used for sensorineural hearing loss), retinal implants (used for retinal pigmentosa), spinal cord stimulators (used for chronic pain, failed back surgery, and ischemia), deep brain stimulators (used for Parkinsons disease, tremors, depression, and others), sacral nerve stimulators (used for urine incontinence and fecal incontinence), vagus nerve stimulators (used for epilepsy and other conditions), transcutaneous electrical nerve stimulators (used for treatment-resistant depression and others), and other electric stimulators (used for gastro paresis, obesity, depression, migraine headaches, and spinal cord injuries).

Feel Free to Talk to Our Research Experts for More Detailed information

On the basis of end user, the bioelectric medicine market is segmented into hospitals, research institutes, and individual users. The hospitals segment is expected to account for the largest share of the market in 2016; while, the individual users segment is projected to grow at the highest CAGR in the forecast period.

Geographically, the global bioelectric medicine market is divided into North America, Europe, Asia-Pacific, and the Rest of the World (Latin America, Middle East, and Africa). North America is expected to account for the largest share of the bioelectric medicine market in 2016, followed by Europe, Asia-Pacific, and the Rest of the World. The Asia-Pacific market is projected to grow at the highest CAGR, and serves as a revenue pocket for companies offering electroceuticals/bioelectric medicine devices.

Major players in the electroceuticals market include Medtronic plc (Ireland), St. Jude Medical, Inc. (U.S.), Boston Scientific Corporation (U.S.), Cochlear Limited (Australia), Sonova Holding AG (Switzerland), LivaNova PLC (U.K.), Biotronik (Germany), Nevro Corporation (U.S.), Second Sight Medical Products, Inc. (U.S.), and ElectroCore LLC (U.S.). Others are BioElectronics Corporation (U.S.), MED-EL (Austria), Cefaly Technology (Belgium), Stimwave LLC (U.S.), Vomaris Innovations, Inc. (U.S.), EnteroMedics Inc. (U.S.), NeuroSigma, Inc. (U.S.), and Oticon Medical (France).

Target Audience:

# Electroceuticals/Bioelectric Medicine Device Manufacturing Companies

# Suppliers and Distributors of Electroceutical/Bioelectric Medicine Devices

# Healthcare Service Providers

# Teaching Hospitals and Academic Medical Centers (AMCs)

# Health Insurance Players

# Research and Consulting Firm

# Medical Research Institutes

# Audiology Centers

# Healthcare Institutions/Providers (Hospitals, Medical Groups, Physician Practices, Diagnostic Centers, and Outpatient Clinics)

# Venture Capitalists

# Community Centers

Electrosurgery Market - Global Growth Strategies Adopted by Major Industry Leaders

The global Electrosurgery Market is expected to grow at a CAGR of 3.9% between 2016 and 2021. Factors such as technological advancements in electrosurgical devices, growing number of medical, aesthetic, and plastic surgeries, rising demand for minimally invasive surgeries, increasing number of ambulatory surgery centers are driving the growth of this market. 

On the other hand, healthcare reforms in the U.S., frequent product recalls, and risks associated with electrosurgical procedures are some of the key factors limiting the growth of the market.

The major players in the global electrosurgery market include Covidien plc (Ireland) (subsidiary of Medtronic (Ireland)), Ethicon, Inc. (U.S.) (subsidiary of Johnson & Johnson (U.S.)), Olympus Corporation (Japan), CONMED Corporation (U.S.), Erbe Elektromedizin GmbH (Germany), Bovie Medical Corporation (U.S.), B. Braun Melsungen AG (Germany), and BOWA-electronic GmbH & Co. KG (Germany). 

Analysis of the market developments between 2013 and 2016 reveals that product launches, regulatory approvals, and expansions were the most widely adopted growth strategies by players in the global electrosurgery market. 

Players adopted these strategies to strengthen their product portfolios and maintain a competitive position in the market. Ethicon, Inc. (U.S.), Olympus Corporation (Japan), Erbe Elektromedizin GmbH (Germany), Bovie Medical Corporation (U.S.), and BOWA-electronic GmbH & Co. KG (Germany) are some of the key players that primarily adopted these strategies. Acquisitions, agreements, and partnerships are some other strategies adopted by market players.

You Can Also Talk to Our Research Experts to Get More Detailed Information on This Study

Covidien plc (Medtronic) (Ireland) held the leading position in the global electrosurgery market in 2015. The company’s electrosurgery product portfolio is segmented in four broad categories–electrosurgical hardware, electrosurgical instruments, smoke evacuation systems, and vessel sealing. The company focuses on product innovation as its key growth strategy to sustain its leadership position in the electrosurgery market. For instance, in 2015, the company invested USD 2.22 billion on R&D activities, as compared to USD 1.64 billion in 2014; an increase of 35.6% as compared to that of the previous year. 

Ethicon, Inc. (subsidiary of Johnson & Johnson (U.S.)) held the second position in the electrosurgery market in 2015. The company offers products in advanced energy, ligation, hernia repair & fixation, surgical stapling, uterine & pelvic surgery, wound closure, and biosurgery. The company primarily focuses on expanding its electrosurgery product portfolio through the development and launch of technologically advanced products in order to strengthen its footprint in the market. For instance, in October 2016, the company launched HARMONIC HD 1000i Shears, its new high-precision ultrasonic shears. 

Stakeholders:

# Electrosurgical Instruments Manufacturing Companies

# Electrosurgical Instruments Accessories Manufacturing Companies

# Medical Device Suppliers and Distributors

# Hospitals and Clinics

# Research Laboratories and Academic Institutes

# Venture Capitalists and Other Government Funding Organizations

# Research and Consulting Firms

Read More@ 
https://www.marketsandmarkets.com/Market-Reports/electrosurgery-market-142006761.html

The Growth Story of Major Industry Leaders in Transfection Equipment Market

The key players in Transfection Equipment Market are continuously striving to gain larger shares and expand their existing product portfolios by agreements, collaborations, and partnerships. The overall market was dominated by Thermo Fisher Scientific Inc. (U.S.), Promega Corporation (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), and QIAGEN N.V. (Netherlands). Other players include Polyplus-transfection SA (France), Bio-Rad Laboratories Inc. (U.S.), Lonza Group (Switzerland), Sigma-Aldrich Corporation (U.S.), Mirus Bio LLC (U.S.), and MaxCyte, Inc. (U.S.).

Thermo Fisher Scientific Inc. to Dominate the Global Transfection Equipment Market

Thermo Fisher Scientific Inc. (U.S.) is leading player in the transfection reagents and equipment market with a market share of ~61.5% in 2015. The company primarily focuses on growth strategies such as acquisitions to add innovative technologies and products to its portfolio, which in turn helps the company to strengthen its presence in the respective markets. 

Thermo Fisher acquired Affymetrix, Inc. (U.S.) in 2016, Advanced Scientifics, Inc. (U.S.) in 2015, and Life Technologies Corporation (U.S.) in 2014. This helped the company to expand its customer base and significantly boost its market share. The company’s major share in the transfection reagents and equipment market can be attributed to its broad product portfolio, years of experience, and extensive distribution channel.

The R&D expenditure of the company for 2015 was USD 690 million, which enabled it to expand its product portfolio in the transfection reagents and equipment market, and to further enhance its customer base. In November 2014, Thermo Fisher Scientific introduced its Lipofectamine MessengerMAX, a high-efficiency transfection reagent for mRNA delivery in neurons and primary cell types. 

You Can Also Talk to Our Research Experts for More Detailed Information

It is five times more efficient as compared to DNA reagents and helps researchers in easy transfection of biologically relevant cell models without electroporation or viruses. The company‘s distribution network comprises a broad sales force and global network of resellers and distributors. Thermo Fisher has approximately 17,500 sales and service personnel, including over 3,000 trained technical specialists who address the diversified demands of technical end users.

Promega Corporation (U.S.) is another dominant player in the transfection reagents and equipment market. The company accounted for approximately ~17.4% of the market revenue generation. The firm offers more than 3000 products for life science research, particularly in genomics, protein analysis and expression, cellular analysis, drug discovery, and genetic identity. It offers various transfection reagents under its reporter assays and transfection category of products. Promega has branches in 16 countries with more than 50 global distributors. 

The company possesses a strong intellectual property portfolio, which helps it to maintain its position in the life science market. Promega owns more than hundred patents in the field of nucleic acid purification, human identification, bioluminescence, coupled in vitro transcription and translation, and cell biology. The company focuses on the strategy of new product development and expansion to strengthen its position in the market.

Players operating in the transfection reagents and equipment market adopted strategies such as agreements, collaborations, and partnerships to strengthen their global presence. The key players that have adopted these strategies include MaxCyte, Inc. (U.S.), Polyplus-transfection SA (France), QIAGEN N.V. (Netherlands), Lonza Group Ltd. (Switzerland), F. Hoffmann-La Roche ltd (Switzerland), and Thermo Fisher Scientific Inc. (U.S.)

Read More@ 
https://www.marketsandmarkets.com/Market-Reports/transfection-reagents-equipment-market-139141146.html

Key Strategies Adopted by Players in the Sleep Apnea Devices Market for Global Growth

The Sleep Apnea Devices Market is projected to reach USD 6.49 Billion by 2023 from an estimated USD 4.44 Billion in 2018, at a CAGR of 7.8%. 

The sleep apnea devices market is dominated by a few players globally. Players in this market compete with each other to deliver superior quality therapeutic and diagnostic products for OSA (Obstructive Sleep Apnea). In 2017, the sleep apnea devices market was dominated by a few large players, namely, ResMed, Inc. (US), Koninklijke Philips (Netherlands), and Fisher & Paykel Healthcare Ltd. (New Zealand).

Product launches, product approvals, acquisitions, agreements, and contracts were the key strategies adopted by players between 2015 and 2018.

Download the PDF Brochure for More Details@ 
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=719

ResMed dominated the sleep apnea devices market in 2017. The company gained a major share in the sleep apnea devices market on account of its diversified product portfolio, widespread geographical presence, and focus on strategies such as innovation and expansions. The company strongly focuses on expansion into new product segments as well as geographies to gain a competitive edge in the market. 

Thus, to enter the high growth market, ResMed acquired Laboratoires Narval, S.A. (France) to supply custom-made mandibular advancement devices. Additionally, in February 2016, ResMed acquired Brightree LLC (US), a provider of cloud-based software solutions for the post-acute care industry. This acquisition strengthened ResMed’s market position as well as significantly expanded its software product portfolio. ResMed also has a strong patent portfolio which helps the company maintain its leadering position in the market.

Koninklijke Philips is the second largest player in the global sleep apnea devices market. The company’s strong position in this market can be attributed to its acquisition of Respironics in 2008, a US-based established manufacturer and distributor of sleep and respiratory products. The company’s wide geographical presence and strong distribution network have also helped it to gain a significant market share. In the past three years, innovation has been the company’s core business strategy to increase its share in the global sleep apnea devices market. 

This strategy is largely supported by the company’s strong R&D activities. The company invested USD 455.91 million (5.8% of its Personal Health segment sales) in R&D in 2017. The company’s rich pool of skilled R&D personnel ensures constant development and launch of technologically advanced products in the market. This further helps Philips to launch products like masks, PAP devices, and ventilators in the market.

Fisher & Paykel Healthcare accounted for the third largest share of the global sleep apnea devices market. The company strongly focuses on developing and establishing a direct sales force in major geographic markets. The company significantly invests in R&D activities to launch technologically advanced products in the market. The company’s rich pool of skilled R&D personnel ensures constant development and launch of advanced products in the market. 

It invested USD 59.94 million, USD 51.29 million, and USD 53.98 million in R&D in 2017, 2016, and 2015, respectively. As a result of its strong R&D activities, the company has launched sleep apnea products like nasal pillow masks, optiflow nasal cannulas, and Airspiral tubes. The growing workforce, strong R&D, and consistent new product launches are likely to help the company gain a greater market share in the coming years.

You Can Also Talk to Our Research Experts to Get More Detailed Information

Other players in the sleep apnea devices market include SomnoMed Ltd. (Australia), Compumedics Limited (Australia), Löwenstein Medical GmbH & Co. KG. (Germany), Whole You, Inc. (US), BMC Medical Co., Ltd. (China), Drive DeVilbiss Healthcare (US), and Braebon Medical Corporation (Canada).

Target Audience:

• Medical devices manufacturing companies
• Medical devices suppliers and distributors
• Diagnostic laboratories
• Hospitals
• Venture capitalists
• Sleep laboratories
• Business research and consulting service providers

Scope of the Report:

The research report categorizes the sleep apnea devices market into the following segments and sub-segments:

Sleep Apnea Devices Market, By Type

• Therapeutic Devices:
  • Positive Airway Pressure (PAP) Devices
    • APAP
    • CPAP
    • BPAP
  • Facial Interfaces
    • Masks
      • Full-face masks
      • Nasal Pillow Masks
      • Nasal Masks
    • Cushions
  • Adaptive Servo-Ventilation (ASV)
  • Accessories
    • Mandibular Advancement Devices
    • Tongue-retaining Devices
  • Oral Appliances
    • Chin Restraints
    • Other Accessories
  • Other Therapeutic Devices
• Diagnostic Devices
  • Polysomnography (PSG) Devices
    • Clinical PSG Devices
    • Ambulatory PSG Devices
  • Home Sleep Testing Devices
  • Oximeters
    • Fingertip Oximeters
    • Handheld Oximeters
    • Wrist-worn Oximeters
    • Tabletop Oximeters
  • Actigraphy Systems
  • Sleep Screening Devices

Sleep Apnea Devices Market, By End User

• Sleep Laboratories & Hospitals
• Home Care/Individuals

Sleep Apnea Devices Market, By Region

• North America
  • US
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe (RoE)
•  APAC
  • Japan
  • China
  • Australia
  • Rest of Asia Pacific (RoAPAC)
• Rest of the World

Read More@ 
https://www.marketsandmarkets.com/Market-Reports/sleep-apnea-devices-market-719.html